Heparin in clinical doses 'primes' granulocytes to subsequent activation as measured by myeloperoxidase release

Scandinavian Journal of Immunology

Volumn 43, Issue 4, 1996, Pages 385-390

  Videm, V ^a,b  

^a UNIVERSITY OF OSLO   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; MYELOPEROXIDASE;

ADULT; ARTICLE; CARDIOPULMONARY BYPASS; ENZYME IMMUNOASSAY; GRANULOCYTE; HUMAN; HUMAN CELL; NORMAL HUMAN; PRIORITY JOURNAL;

EID: 0029864755     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.1996.d01-57.x     Document Type: Article

References (25)

1. John LCH, Rees GM, Kovacs IB. Inhibition of platelet function by heparin. An etiologic factor in postbypass hemorrhage. J Thorac Cardiovasc Surg 1993;105:816-22.
2. Kazatchkine MD, Fearon DT, Metcalfe DD, Rosenberg RD, Austen KF. Structural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase. J Clin Invest 1981;67:223-8.
3. Weiler JM, Yurt RW, Fearon DT, Austen KF. Modulation of the formation of the amplification convertase of complement, C3b,Bb, by native and commercial heparin. J Exp Med 1978;147:409-21.
4. Kongsgaard UE, Smith-Erichsen N, Geiran O, Amundsen E, Mollnes TE, Garred P. Different activation patterns in the plasma kallikrein-kinin and complement systems during coronary bypass surgery. Acta Anaesthesiol Scand 1990;33:343-7.
5. Kongsgaard UE, Smith-Erichsen N, Geiran O, Bjørnskau L. Changes in the coagulation and fibrinolytic systems during and after cardiopulmonary bypass surgery. Thorac Cardiovasc Surg 1989;37:158-62.
6. Bazzoni G, Nuñez AB, Mascellani G, Bianchini P, Dejana E, del Maschio A. Effect of heparin, dermatan sulfate, and related oligo-derivatives on human polymorphonuclear leukocyte functions. J Lab Clin Med 1993;121:268-75.
7. Silvestro L, Viano I, Macario M et al. Effects of heparin and its desulfated derivatives on leukocyte-endothelial adhesion. Semin Thromb Hemost 1994;20:254-8.
8. Arfors KE, Ley K. Sulfated polysaccharides in inflammation. J Lab Clin Med 1993;121:201-2 (Editorial).
9. Dziarski R. Enhancement of mixed leukocyte reaction and cytotoxic antitumor responses by heparin. J Immunol 1989;143:356-65.
10. Videm V, Fosse E, Mollnes TE, Garred P, Svennevig JL. Complement activation with bubble and membrane oxygenators in aortocoronary bypass grafting. Ann Thorac Surg 1990;50:387-91.
11. Suzuki K, Ota H, Sasagawa S, Sakatani T, Fujikura T. Assay method for myeloperoxidase in human polymorphonuclear leukocytes. Analyt Biochem 1983;132:345-52.
12. Bøyum A. Isolation of mononuclear cells and granulocytes from human blood. Scand J Clin Lab Invest 1968;21(Suppl. 97):77-89.
13. Bazzoni G, Dejana E, del Maschio A. Platelet-neutrophil interactions. Possible relevance in the pathogenesis of thrombosis and inflammation. Haematologica 1991;76:491-9.
14. Bruil A, Terlingen JGA, Beugeling T, van Aken WG, Feijen J. In vitro leucocyte adhesion to modified polyurethane surfaces. Biomaterials 1992;13:915-23.
15. Olsson I, Venge P. Cationic proteins of human granulocytes. II. Separation of the cationic proteins of the granules of leukemic myeloid cells. Blood 1974;44:235-46.
16. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriphage T4. Nature 1970;227:680-5.
17. Conover WJ. Practical Nonparametric Statistics. 2nd edition, New York: John Wiley, 1980:229-37.
18. Bakkenist ARJ, Wever R, Vulsma T, Plat H, van Gelder BF. Isolation procedure and some properties of myeloperoxidase from human leucocytes. Biochim Biophys Acta 1978;524:45-54.
19. Pincemail J, Deby-Dupont G, Deby C et al. Fast double antibody radioimmunoassay of human granulocyte myeloperoxidase and its application to plasma. J Immunol Methods 1991;137:181-91.
20. Vilja P, Lumikari M, Tenovuo J, Sievers G, Tuohimaa P. Sensitive immunometric assays for secretory peroxidase and myeloperoxidase in human saliva. J Immunol Methods 1991;141:277-84.
21. Ihrcke NS, Wrenshall LE, Lindman BJ, Platt JL. Role of heparan sulfate in immune system-blood vessel interactions. Immunology Today 1993;14:500-5.
22. Key ND, Platt JL, Vercellotti GM. Vascular endothelial cell proteoglycans are susceptible to cleavage by neutrophils. Arteriosclerosis Thrombosis 1992;12:836-42.
23. Gravlee GP, Haddon WS, Rothberger HK et al. Heparin dosing and monitoring for cardiopulmonary bypass. J Thorac Cardiovasc Surg 1990:;99:518-27.
24. Culliford AT, Gitel SN, Starr N et al. Lack of correlation between activated clotting time and plasma heparin during cardiopulmonary bypass. Ann Surg 1981;193:105-11.
25. Øvrum E, Mollnes TE, Fosse E et al. High and low systemic heparin dose with completely heparin-coated cardiopulmonary bypass: Activation of complement and granulocytes. Ann Thorac Surg (in press).